89bio Inc (ETNB)

Currency in USD
9.01
-0.01(-0.11%)
Real-time Data·
ETNB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ETNB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.489.07
52 wk Range
4.1611.84
Key Statistics
Prev. Close
9.02
Open
8.58
Day's Range
8.48-9.07
52 wk Range
4.16-11.84
Volume
914.64K
Average Volume (3m)
1.88M
1-Year Change
16.99%
Book Value / Share
4.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ETNB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.45
Upside
+226.91%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

89bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

89bio Inc Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

89bio Inc SWOT Analysis


Pegozafermin Promise
Explore 89bio's lead candidate pegozafermin, poised to disrupt MASH and SHTG treatment landscapes with its potential billion-dollar market opportunities
Clinical Milestones
Delve into 89bio's ongoing Phase 3 trials and the significance of upcoming competitor data in shaping the company's future prospects
Market Dynamics
Learn how 89bio navigates the evolving MASH treatment landscape, positioning pegozafermin against emerging therapies and potential market shifts
Financial Outlook
Analyst price targets range from $12 to $49, with potential for significant upside based on clinical outcomes and market positioning
Read full SWOT analysis

Compare ETNB to Peers and Sector

Metrics to compare
ETNB
Peers
Sector
Relationship
P/E Ratio
−3.3x−4.6x−0.5x
PEG Ratio
0.05−0.060.00
Price/Book
2.1x2.7x2.6x
Price / LTM Sales
-151.9x3.3x
Upside (Analyst Target)
210.4%191.6%43.4%
Fair Value Upside
Unlock4.9%7.1%Unlock

Analyst Ratings

9 Buy
2 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.45
(+226.91% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.71 / -0.50
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ETNB Income Statement

People Also Watch

250.41
AVAV
-3.55%
28.23
VCYT
+1.99%
18.04
URGN
-2.96%
50.01
AKRO
-0.87%
12.12
OCUL
-1.46%

FAQ

What Stock Exchange Does 89bio Trade On?

89bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for 89bio?

The stock symbol for 89bio is "ETNB."

What Is the 89bio Market Cap?

As of today, 89bio market cap is 1.30B.

What Is 89bio's Earnings Per Share (TTM)?

The 89bio EPS (TTM) is -3.30.

When Is the Next 89bio Earnings Date?

89bio will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is ETNB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has 89bio Stock Split?

89bio has split 0 times.

How Many Employees Does 89bio Have?

89bio has 93 employees.

What is the current trading status of 89bio (ETNB)?

As of 08 Aug 2025, 89bio (ETNB) is trading at a price of 9.01, with a previous close of 9.02. The stock has fluctuated within a day range of 8.48 to 9.07, while its 52-week range spans from 4.16 to 11.84.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.